STAT3 and neoplasm: Our findings demonstrate that targeting STAT3 signaling in neutrophils presents a therapeutic opportunity to convert immunogenic “cold” tumors into a more immunogenic “hot” state, thereby enhancing cytotoxic T cell responses across different tumor types and suggesting that it could significantly improve the response to checkpoint therapy in vivo (Fig. 6).